Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study
DeMichele et al.
JCO 2008;26:4151-4159.
ABSTRACT
| FULL TEXT
Metabolism, Distribution, and Excretion of a Next Generation Selective Estrogen Receptor Modulator, Lasofoxifene, in Rats and Monkeys
Prakash et al.
Drug Metab. Dispos. 2008;36:1753-1769.
ABSTRACT
| FULL TEXT
Impact of Economic, Regulatory, and Patent Policies on Innovation in Cancer Chemoprevention
Grabowski and Moe
Cancer Prevention Research 2008;1:84-90.
ABSTRACT
| FULL TEXT
The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death?
Jordan
JCO 2008;26:3073-3082.
ABSTRACT
| FULL TEXT
Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk
Grady et al.
JNCI J Natl Cancer Inst 2008;100:854-861.
ABSTRACT
| FULL TEXT
The Rise of Raloxifene and the Fall of Invasive Breast Cancer
Jordan
JNCI J Natl Cancer Inst 2008;100:831-833.
FULL TEXT
Selective Estrogen Receptor Modulators Accelerate Cutaneous Wound Healing in Ovariectomized Female Mice
Hardman et al.
Endocrinology 2008;149:551-557.
ABSTRACT
| FULL TEXT
Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer
Jordan and O'Malley
JCO 2007;25:5815-5824.
ABSTRACT
| FULL TEXT
Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point
Jordan
Cancer Epidemiol. Biomarkers Prev. 2007;16:2207-2209.
FULL TEXT
Tamoxifen or Raloxifene in Postmenopausal Women for Prevention of Breast Cancer: A Tale of Two Choices Counterpoint
Fabian
Cancer Epidemiol. Biomarkers Prev. 2007;16:2210-2212.
FULL TEXT
Chemoprevention Clinical Trials: It Is Time to Turn Success into Progress
Brown
Cancer Epidemiol. Biomarkers Prev. 2007;16:1531-1532.
FULL TEXT
The 2.0 A crystal structure of the ER{alpha} ligand-binding domain complexed with lasofoxifene
Vajdos et al.
Protein Sci. 2007;16:897-905.
ABSTRACT
| FULL TEXT
A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor Modulator
Madauss et al.
Mol. Endocrinol. 2007;21:1066-1081.
ABSTRACT
| FULL TEXT
Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and the Risk of Breast Cancer
Baglietto et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:763-768.
ABSTRACT
| FULL TEXT
SERMs: Meeting the Promise of Multifunctional Medicines
Jordan
JNCI J Natl Cancer Inst 2007;99:350-356.
ABSTRACT
| FULL TEXT
Results of MRI Screening for Breast Cancer in High-Risk Patients with LCIS and Atypical Hyperplasia
Port et al.
Ann. Surg. Oncol. 2007;14:1051-1057.
ABSTRACT
| FULL TEXT
Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial
Powles et al.
JNCI J Natl Cancer Inst 2007;99:283-290.
ABSTRACT
| FULL TEXT
Selective Activation of Estrogen Receptor-{beta} Transcriptional Pathways by an Herbal Extract
Cvoro et al.
Endocrinology 2007;148:538-547.
ABSTRACT
| FULL TEXT
Osteoporosis and its management
Poole and Compston
BMJ 2006;333:1251-1256.
FULL TEXT
Identification of Biomarkers Modulated by the Rexinoid LGD1069 (Bexarotene) in Human Breast Cells Using Oligonucleotide Arrays
Kim et al.
Cancer Res. 2006;66:12009-12018.
ABSTRACT
| FULL TEXT
Effect of raloxifene on salivary sex steroid concentrations in premenopausal women
Chatterton et al.
J Endocrinol 2006;191:599-604.
ABSTRACT
| FULL TEXT
Raloxifene and tamoxifen had similar efficacy for preventing invasive breast cancer in women at increased risk
Stearns
Evid. Based Med. 2006;11:177-177.
FULL TEXT
Commentary on Mobley and Others: Importance of Assumptions About VTE Mortality in Modeling the Cost-effectiveness of Osteoporosis Therapies.
Meadows et al.
Med Decis Making 2006;26:633-635.
Skeletal complications of breast cancer therapies.
Hirbe et al.
Clin. Cancer Res. 2006;12:6309s-6314s.
ABSTRACT
| FULL TEXT
Effect of Raloxifene on Bone Mineral Density in Premenopausal Women at Increased Risk of Breast Cancer
Eng-Wong et al.
J. Clin. Endocrinol. Metab. 2006;91:3941-3946.
ABSTRACT
| FULL TEXT
The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor-Negative Model of Breast Cancer.
Liby et al.
Clin. Cancer Res. 2006;12:5902-5909.
ABSTRACT
| FULL TEXT
Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.
Kendall and Dowsett
Endocr Relat Cancer 2006;13:827-837.
ABSTRACT
| FULL TEXT
The Science of Selective Estrogen Receptor Modulators: Concept to Clinical Practice
Jordan
Clin. Cancer Res. 2006;12:5010-5013.
FULL TEXT
Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk
Lippman et al.
Clin. Cancer Res. 2006;12:5242-5247.
ABSTRACT
| FULL TEXT
Raloxifene Increases Proliferation and Up-regulates Telomerase Activity in Human Umbilical Vein Endothelial Cells
Doshida et al.
J. Biol. Chem. 2006;281:24270-24278.
ABSTRACT
| FULL TEXT
Risk-benefit profiles of raloxifene for women.
Stefanick
NEJM 2006;355:190-192.
FULL TEXT
Hip fracture.
Parker and Johansen
BMJ 2006;333:27-30.
FULL TEXT
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Vogel et al.
JAMA 2006;295:2727-2741.
ABSTRACT
| FULL TEXT
Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Land et al.
JAMA 2006;295:2742-2751.
ABSTRACT
| FULL TEXT
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Kelloff et al.
Clin. Cancer Res. 2006;12:3661-3697.
ABSTRACT
| FULL TEXT
Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.
Labrie
Endocr Relat Cancer 2006;13:335-355.
ABSTRACT
| FULL TEXT
Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.
Faupel-Badger et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:1153-1158.
ABSTRACT
| FULL TEXT
Endocrine Regulation of HOX Genes
Daftary and Taylor
Endocr. Rev. 2006;27:331-355.
ABSTRACT
| FULL TEXT
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan et al.
Clin. Cancer Res. 2006;12:2255-2263.
ABSTRACT
| FULL TEXT
Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.
Mobley et al.
Med Decis Making 2006;26:194-206.
ABSTRACT
Diet Quality Is Associated with the Risk of Estrogen Receptor-Negative Breast Cancer in Postmenopausal Women
Fung et al.
J. Nutr. 2006;136:466-472.
ABSTRACT
| FULL TEXT
Endogenous Sex Hormones, Breast Cancer Risk, and Tamoxifen Response: An Ancillary Study in the NSABP Breast Cancer Prevention Trial (P-1)
Beattie et al.
JNCI J Natl Cancer Inst 2006;98:110-115.
ABSTRACT
| FULL TEXT
Breast Cancer Risk Reduction Options: Awareness, Discussion, and Use among Women from Four Ethnic Groups
Kaplan et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:162-166.
ABSTRACT
| FULL TEXT
Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
Fisher et al.
JNCI J Natl Cancer Inst 2005;97:1652-1662.
ABSTRACT
| FULL TEXT
Is dehydroepiandrosterone a hormone?
Labrie et al.
J Endocrinol 2005;187:169-196.
ABSTRACT
| FULL TEXT
Endometrial Effects of Bazedoxifene Acetate, a Novel Selective Estrogen Receptor Modulator, in Postmenopausal Women
Ronkin
Obstet Gynecol 2005;106:1111-1111.
FULL TEXT
Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force
Nelson et al.
ANN INTERN MED 2005;143:362-379.
ABSTRACT
| FULL TEXT
Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Komm et al.
Endocrinology 2005;146:3999-4008.
ABSTRACT
| FULL TEXT
Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis
Bouker et al.
Carcinogenesis 2005;26:1527-1535.
ABSTRACT
| FULL TEXT
Postmenopausal Osteoporosis
Rosen
NEJM 2005;353:595-603.
FULL TEXT
Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review
Dietel et al.
Hum Reprod 2005;20:2052-2060.
ABSTRACT
| FULL TEXT
Comparison of the Metabolic Effects of Raloxifene and Oral Estrogen in Postmenopausal and Growth Hormone-Deficient Women
Gibney et al.
J. Clin. Endocrinol. Metab. 2005;90:3897-3903.
ABSTRACT
| FULL TEXT
Breast-tissue sampling for risk assessment and prevention
Fabian et al.
Endocr Relat Cancer 2005;12:185-213.
ABSTRACT
| FULL TEXT
Molecular Biology of the 3{beta}-Hydroxysteroid Dehydrogenase/{Delta}5-{Delta}4 Isomerase Gene Family
Simard et al.
Endocr. Rev. 2005;26:525-582.
ABSTRACT
| FULL TEXT
Endometrial Effects of Bazedoxifene Acetate, a Novel Selective Estrogen Receptor Modulator, in Postmenopausal Women
Ronkin et al.
Obstet Gynecol 2005;105:1397-1404.
ABSTRACT
| FULL TEXT
Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor
Zeng et al.
Carcinogenesis 2005;26:1109-1116.
ABSTRACT
| FULL TEXT
Sex Hormones, Risk Factors, and Risk of Estrogen Receptor-Positive Breast Cancer in Older Women: A Long-term Prospective Study
Cummings et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1047-1051.
ABSTRACT
| FULL TEXT
Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump
Taylor and Taguchi
Ann Fam Med 2005;3:242-247.
ABSTRACT
| FULL TEXT
Aromatase Inhibitors as Adjuvant Therapy for Postmenopausal Patients With Early Stage Breast Cancer
Kudachadkar and O'Regan
CA Cancer J Clin 2005;55:145-163.
ABSTRACT
| FULL TEXT
Malignant Mixed Mullerian Tumor of the Uterus in a Patient Taking Raloxifene
Goldman et al.
Obstet Gynecol 2005;105:1278-1280.
ABSTRACT
| FULL TEXT
Differential effects of 17{beta}-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets
Jayachandran et al.
Am. J. Physiol. Heart Circ. Physiol. 2005;288:H2355-H2362.
ABSTRACT
| FULL TEXT
The Retinoid X Receptor-Selective Retinoid, LGD1069, Down-regulates Cyclooxygenase-2 Expression in Human Breast Cells through Transcription Factor Crosstalk: Implications for Molecular-Based Chemoprevention
Kong et al.
Cancer Res. 2005;65:3462-3469.
ABSTRACT
| FULL TEXT
Tamoxifen Inhibition of Estrogen Receptor-{alpha}-Negative Mouse Mammary Tumorigenesis
Medina et al.
Cancer Res. 2005;65:3493-3496.
ABSTRACT
| FULL TEXT
Epidemiology and Prevention of Breast Cancer
Colditz
Cancer Epidemiol. Biomarkers Prev. 2005;14:768-772.
FULL TEXT
Hormonal Interventions: From Adjuvant Therapy to Breast Cancer Prevention
Dunn
aacredbook 2005;2005:185-188.
FULL TEXT
Breast Cancer Chemoprevention: Biomarker End-Point Trials
Brown
aacredbook 2005;2005:189-191.
FULL TEXT
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
Fabian and Kimler
JCO 2005;23:1644-1655.
FULL TEXT
The Effects of Tamoxifen and Its Metabolites on Platelet Function and Release of Reactive Oxygen Intermediates
Vitseva et al.
J. Pharmacol. Exp. Ther. 2005;312:1144-1150.
ABSTRACT
| FULL TEXT
Effect of Tamoxifen on Venous Thromboembolic Events in a Breast Cancer Prevention Trial
Decensi et al.
Circulation 2005;111:650-656.
ABSTRACT
| FULL TEXT
Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer
Colditz
Clin. Cancer Res. 2005;11:909s-917s.
ABSTRACT
| FULL TEXT
Exemestane for Breast Cancer Prevention: A Feasible Strategy?
Lonning
Clin. Cancer Res. 2005;11:918s-924s.
ABSTRACT
| FULL TEXT
Tamoxifen versus Aromatase Inhibitors for Breast Cancer Prevention
Yue et al.
Clin. Cancer Res. 2005;11:925s-930s.
ABSTRACT
| FULL TEXT
Prevention of Hormone-Related Cancers: Breast Cancer
Dunn et al.
JCO 2005;23:357-367.
ABSTRACT
| FULL TEXT
Cell- and Ligand-specific Regulation of Promoters Containing Activator Protein-1 and Sp1 Sites by Estrogen Receptors {alpha} and {beta}
Schultz et al.
J. Biol. Chem. 2005;280:347-354.
ABSTRACT
| FULL TEXT
Endogenous Estrogen, Androgen, and Progesterone Concentrations and Breast Cancer Risk Among Postmenopausal Women
Missmer et al.
JNCI J Natl Cancer Inst 2004;96:1856-1865.
ABSTRACT
| FULL TEXT
A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity
Stearns et al.
Clin. Cancer Res. 2004;10:8332-8340.
ABSTRACT
| FULL TEXT
Both estrogen and raloxifene protect against {beta}-amyloid-induced neurotoxicity in estrogen receptor {alpha}-transfected PC12 cells by activation of telomerase activity via Akt cascade
Du et al.
J Endocrinol 2004;183:605-615.
ABSTRACT
| FULL TEXT
Mammographic Density and Estrogen Receptor Status of Breast Cancer
Ziv et al.
Cancer Epidemiol. Biomarkers Prev. 2004;13:2090-2095.
ABSTRACT
| FULL TEXT
Defining the Role of Raloxifene for the Prevention of Breast Cancer
Kalidas et al.
JNCI J Natl Cancer Inst 2004;96:1731-1733.
FULL TEXT
Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene
Martino et al.
JNCI J Natl Cancer Inst 2004;96:1751-1761.
ABSTRACT
| FULL TEXT
Clinical Trials in Cancer Prevention: Current Results and Perspectives for the Future
Greenwald
J. Nutr. 2004;134:3507S-3512S.
ABSTRACT
| FULL TEXT
A Pilot Surrogate End Point Biomarker Trial of Perillyl Alcohol in Breast Neoplasia
Stearns et al.
Clin. Cancer Res. 2004;10:7583-7591.
ABSTRACT
| FULL TEXT
Risk of ischemic stroke with tamoxifen treatment for breast cancer: A meta-analysis
Bushnell and Goldstein
Neurology 2004;63:1230-1233.
ABSTRACT
| FULL TEXT
Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation
Grady et al.
Obstet Gynecol 2004;104:837-844.
ABSTRACT
| FULL TEXT
Breast Cancer Risk in Primary Care: Implications for Chemoprevention
Lewis et al.
Arch Intern Med 2004;164:1897-1903.
ABSTRACT
| FULL TEXT
The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death
Osipo et al.
Exp. Biol. Med. 2004;229:722-731.
ABSTRACT
| FULL TEXT
Arzoxifene: A Promising New Selective Estrogen Receptor Modulator for Clinical Chemoprevention of Breast Cancer: Commentary re C. J. Fabian et al., Breast Cancer Chemoprevention Phase I Evaluation of Biomarker Modulation by Arzoxifene, a Third Generation Selective Estrogen Receptor Modulator. Clin Cancer Res 2004;10:5403-17.
Sporn
Clin. Cancer Res. 2004;10:5313-5315.
FULL TEXT
Hormones and breast cancer
ESHRE Capri Workshop Group
Hum Reprod Update 2004;10:281-293.
ABSTRACT
| FULL TEXT
A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women
Reid et al.
Arch Intern Med 2004;164:871-879.
ABSTRACT
| FULL TEXT
Deja Vu for Breast Cancer Two?
Stearns and Davidson
JNCI J Natl Cancer Inst 2004;96:497-499.
FULL TEXT
Estrogen Receptor Status of Primary Breast Cancer Is Predictive of Estrogen Receptor Status of Contralateral Breast Cancer
Swain et al.
JNCI J Natl Cancer Inst 2004;96:516-523.
ABSTRACT
| FULL TEXT
Long-Term Treatment of Lasofoxifene Preserves Bone Mass and Bone Strength and Does Not Adversely Affect the Uterus in Ovariectomized Rats
Ke et al.
Endocrinology 2004;145:1996-2005.
ABSTRACT
| FULL TEXT
The Role of Selective Estrogen Receptor Modulators in the Prevention of Breast Cancer: Comparison of the Clinical Trials
Martino et al.
The Oncologist 2004;9:116-125.
ABSTRACT
| FULL TEXT
The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial
Clowes et al.
J. Clin. Endocrinol. Metab. 2004;89:1117-1123.
ABSTRACT
| FULL TEXT
Estradiol and Selective Estrogen Receptor Modulators Differentially Regulate Target Genes with Estrogen Receptors {alpha} and {beta}
Kian Tee et al.
Mol. Biol. Cell 2004;15:1262-1272.
ABSTRACT
| FULL TEXT
Selective Estrogen Receptor Modulators: Discrimination of Agonistic versus Antagonistic Activities by Gene Expression Profiling in Breast Cancer Cells
Frasor et al.
Cancer Res. 2004;64:1522-1533.
ABSTRACT
| FULL TEXT
